{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:51:01Z","timestamp":1790661061484,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T00:00:00Z","timestamp":1281484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s12325-010-0057-y","type":"journal-article","created":{"date-parts":[[2010,8,16]],"date-time":"2010-08-16T23:56:57Z","timestamp":1282003017000},"page":"581-590","source":"Crossref","is-referenced-by-count":22,"title":["Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation"],"prefix":"10.1007","volume":"27","author":[{"given":"Stefan","family":"Mueller-Lissner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,11]]},"reference":[{"key":"57_CR1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2982.2004.00513.x","volume":"16","author":"H.U. Schepper De","year":"2004","unstructured":"De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16:383\u2013394.","journal-title":"Neurogastroenterol Motil"},{"key":"57_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199302000-00001","volume":"16","author":"G.W. Pasternak","year":"1993","unstructured":"Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol. 1993;16:1\u201318.","journal-title":"Clin Neuropharmacol"},{"key":"57_CR3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/00000542-199710000-00008","volume":"87","author":"D.B. Murphy","year":"1997","unstructured":"Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology. 1997;87:765\u2013770.","journal-title":"Anesthesiology"},{"key":"57_CR4","unstructured":"Smith KJ, Hopp M, Mundin G, Bond S, Connor A. Oxycodone\/Naloxone prolonged release tablets reduce oxycodone-induced prolongation of gastrointestinal transit. 5th World Congress of the World Institute of Pain, New York, NY, USA; March 13\u201316, 2009."},{"key":"57_CR5","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/0016-5085(88)90673-7","volume":"94","author":"P.N. Kaufman","year":"1988","unstructured":"Kaufman PN, Krevsky B, Malmud LS, et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology. 1988;94:1351\u20131356.","journal-title":"Gastroenterology"},{"key":"57_CR6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0022-3565(25)11008-2","volume":"243","author":"J. Shook","year":"1987","unstructured":"Shook J, Pelton JP, Hruby VJ, Burks TF. Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther. 1987;243:492\u2013500.","journal-title":"J Pharmacol Exp Ther"},{"key":"57_CR7","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","volume":"130","author":"G. Longstreth","year":"2006","unstructured":"Longstreth G, Thompson W, Chey W, Houghton L, Mearin F, Spiller R. Functional bowel disorders. Gastroenterology. 2006;130:1480\u20131491.","journal-title":"Gastroenterology"},{"key":"57_CR8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","volume":"10","author":"T.J. Bell","year":"2009","unstructured":"Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35\u201342.","journal-title":"Pain Med"},{"key":"57_CR9","doi-asserted-by":"crossref","first-page":"R1046","DOI":"10.1186\/ar1782","volume":"7","author":"R.A. Moore","year":"2005","unstructured":"Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7:R1046\u20131051.","journal-title":"Arthritis Res Ther"},{"key":"57_CR10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ageing\/15.3.182","volume":"15","author":"J.A.H. Puxty","year":"1986","unstructured":"Puxty JAH, Fox RA. Golytely: a new approach to faecal impaction in old age. Age Ageing. 1986;15:182\u2013184.","journal-title":"Age Ageing"},{"key":"57_CR11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1365-2036.2008.03689.x","volume":"27","author":"S.F. Cook","year":"2008","unstructured":"Cook SF, Lanza L, Zhou X, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27:1224\u20131232.","journal-title":"Aliment Pharmacol Ther"},{"key":"57_CR12","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1097\/01.brs.0000186860.23078.a8","volume":"30","author":"L. Allan","year":"2005","unstructured":"Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid na\u0131ve patients with chronic low back pain. Spine. 2005;30:2484\u20132490.","journal-title":"Spine"},{"key":"57_CR13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2710.2008.00949.x","volume":"33","author":"E.C. Davies","year":"2008","unstructured":"Davies EC, Green CF, Mottram DR, Pirmohamed M. The use of opioids and laxatives, and incidence of constipation, in patients requiring neck-of-femur (NOF) surgery: a pilot study. J Clin Pharm Ther. 2008;33:561\u2013566.","journal-title":"J Clin Pharm Ther"},{"key":"57_CR14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00520-007-0373-1","volume":"16","author":"J. Droney","year":"2008","unstructured":"Droney J, Ross J, Gretton S, Welsh K, Sato H, Riley J. Constipation in cancer patients on morphine. Support Care Cancer. 2008;16:453\u2013459.","journal-title":"Support Care Cancer"},{"key":"57_CR15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.clinthera.2007.05.016","volume":"29","author":"M. Hale","year":"2007","unstructured":"Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther. 2007;29:874\u2013888.","journal-title":"Clin Ther"},{"key":"57_CR16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpain.2006.09.011","volume":"8","author":"M.E. Hale","year":"2007","unstructured":"Hale ME, Ahdieh H, Ma T, Rauck R; Oxymorphone ER Study Group 1. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8:175\u2013184.","journal-title":"J Pain"},{"key":"57_CR17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jpainsymman.2007.10.023","volume":"36","author":"H.G. Kress","year":"2008","unstructured":"Kress HG, Von der Laage D, Hoerauf KH, et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J Pain Symptom Manage. 2008;36:268\u2013779.","journal-title":"J Pain Symptom Manage"},{"key":"57_CR18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1197\/j.aem.2004.12.005","volume":"12","author":"C.A. Marco","year":"2005","unstructured":"Marco CA, Plewa MC, Buderer N, Black C, Roberts A. Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial. Acad Emerg Med. 2005;12:282\u2013288.","journal-title":"Acad Emerg Med"},{"key":"57_CR19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1526-4637.2005.00057.x","volume":"6","author":"A.K. Matsumoto","year":"2005","unstructured":"Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. 2005;6:357\u2013366.","journal-title":"Pain Med"},{"key":"57_CR20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/AJP.0b013e31802b582f","volume":"23","author":"R.K. Portenoy","year":"2007","unstructured":"Portenoy RK, Farrar JT, Backonja MM, et al. Longterm use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain. 2007;23:287\u2013299.","journal-title":"Clin J Pain"},{"key":"57_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.SMJ.0000109215.54052.D8","volume":"97","author":"P.S. Staats","year":"2004","unstructured":"Staats PS, Markowitz J, Schein J. Incidence of constipation associated with longacting opioid therapy: A comparative study. South Med Journal. 2004;97:129\u2013134.","journal-title":"South Med Journal"},{"key":"57_CR22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2982.2009.01458.x","volume":"22","author":"A.K. Tuteja","year":"2010","unstructured":"Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010;22:424\u2013430.","journal-title":"Neurogastroenterol Motil"},{"key":"57_CR23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.clinthera.2006.01.010","volume":"28","author":"S.M. Weinstein","year":"2006","unstructured":"Weinstein SM, Shi M, Buckley BJ, Kwarcinski MA. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. Clin Ther. 2006;28:86\u201398.","journal-title":"Clin Ther"},{"key":"57_CR24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ejpain.2008.09.005","volume":"13","author":"S. Wirz","year":"2009","unstructured":"Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009;13:737\u2013743.","journal-title":"Eur J Pain"},{"key":"57_CR25","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1742-1241.2007.01415.x","volume":"61","author":"S.J. Panchal","year":"2007","unstructured":"Panchal SJ, M\u00fcller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181\u20131187.","journal-title":"Int J Clin Pract"},{"key":"57_CR26","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/S0002-9610(01)00782-6","volume":"1825ASuppl.","author":"M. Pappagallo","year":"2001","unstructured":"Pappagallo, M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl.):11S\u201318S.","journal-title":"Am J Surg"},{"key":"57_CR27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2710.2002.00385.x","volume":"27","author":"M. L. Bouvy","year":"2002","unstructured":"Bouvy M L, Buurma H, Egberts TCG. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. J Clin Pharm Ther. 2002;27;107\u2013110.","journal-title":"J Clin Pharm Ther"},{"key":"57_CR28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jpainsymman.2007.01.017","volume":"35","author":"J. Thomas","year":"2008","unstructured":"Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage. 2008;35:103\u2013113.","journal-title":"J Pain Symptom Manage"},{"key":"57_CR29","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/j.1552-4604.1997.tb04264.x","volume":"37","author":"M.D. Freedman","year":"1997","unstructured":"Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350\/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol. 1997;37:904\u2013907.","journal-title":"J Clin Pharmacol"},{"key":"57_CR30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/jpm.2007.0178","volume":"11","author":"P.H. Hawley","year":"2008","unstructured":"Hawley PH, Byeon JJ. A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Pall Med. 2008;11:575\u2013581.","journal-title":"J Pall Med"},{"key":"57_CR31","doi-asserted-by":"crossref","first-page":"A92","DOI":"10.1016\/S0016-5085(08)60432-1","volume":"134","author":"D.E. Moulin","year":"2008","unstructured":"Moulin DE, Rykx A, Kerstens R, Vandenplassche L. Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor) in patients with opioid-induced constipation. Gastroenterol. 2008;134:A92.","journal-title":"Gastroenterol"},{"key":"57_CR32","first-page":"3070","volume":"147","author":"O. Olsen","year":"1985","unstructured":"Olsen O, H\u00e5kansson T, Forrest JI. Bisocadyl in the treatment of postoperative intestinal atony. Ugeskr Laeger. 1985;147:3070\u20133071.","journal-title":"Ugeskr Laeger"},{"key":"57_CR33","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1526-4637.2007.00335.x","volume":"9","author":"E. McNicol","year":"2008","unstructured":"McNicol E, Boyce DB, Schumann R, Carr D. Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials. Pain Med. 2008;9:634\u2013659.","journal-title":"Pain Med"},{"key":"57_CR34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jpainsymman.2009.02.234","volume":"38","author":"B.H. Chamberlain","year":"2009","unstructured":"Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009;38:683\u2013690.","journal-title":"J Pain Symptom Manage"},{"key":"57_CR35","first-page":"39","volume":"7","author":"N. Slatkin","year":"2009","unstructured":"Slatkin N, Thomas JT, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7:39\u201346.","journal-title":"J Support Oncol"},{"key":"57_CR36","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","volume":"358","author":"J. Thomas","year":"2008","unstructured":"Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008:358:2332\u20132343.","journal-title":"N Engl J Med"},{"key":"57_CR37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2036.2008.03696.x","volume":"28","author":"M.W. B\u00fcchler","year":"2008","unstructured":"B\u00fcchler MW, Seiler CM, Monson JR, et al. Clinical trial: alvimopan for the management of postoperative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008;28:312\u2013325.","journal-title":"Aliment Pharmacol Ther"},{"key":"57_CR38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archsurg.143.11.1098","volume":"143","author":"K. Ludwig","year":"2008","unstructured":"Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg. 2008;143:1098\u20131105.","journal-title":"Arch Surg"},{"key":"57_CR39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/01.sla.0000141158.27977.66","volume":"240","author":"B.G. Wolff","year":"2004","unstructured":"Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting opioid antagonist. Ann Surg. 2004;240:728\u2013735.","journal-title":"Ann Surg"},{"key":"57_CR40","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/clpt.1992.176","volume":"52","author":"K.P. Leow","year":"1992","unstructured":"Leow KP, Smith MT, Williams B, Cramond T. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther. 1992;52:487\u2013495.","journal-title":"Clin Pharmacol Ther"},{"key":"57_CR41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0149-2918(96)80182-2","volume":"18","author":"R.F. Reder","year":"1996","unstructured":"Reder RF, Oshlack B, Miotto JB, Benziger DD, Kaiko RF. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther. 1996;18:95\u2013105.","journal-title":"Clin Ther"},{"key":"57_CR42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00045391-200107000-00004","volume":"8","author":"R.D. Colucci","year":"2001","unstructured":"Colucci RD, Swanton RE, Thomas GB, Kaiko RF. Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine. Am J Ther. 2001;8:231\u2013236.","journal-title":"Am J Ther"},{"key":"57_CR43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1090-3801(98)90020-9","volume":"2","author":"P. Mucci-LoRusso","year":"1998","unstructured":"Mucci-LoRusso P, Berman BS. Silberstein PT, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, paraIlel-group study. Eur J Pain. 1998;2:233\u2013249.","journal-title":"Eur J Pain"},{"key":"57_CR44","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0022-3565(25)29707-5","volume":"187","author":"J. Fishman","year":"1973","unstructured":"Fishman J, Roffwarg H, Hellman L. Disposition of naloxone-7,8-3H in normal and narcotic dependent men. J Pharmacol Exp Ther. 1973;187:575\u2013580.","journal-title":"J Pharmacol Exp Ther"},{"key":"57_CR45","first-page":"525","volume":"8","author":"S.H. Weinstein","year":"1973","unstructured":"Weinstein SH, Pfeffer M, Schor JM. Metabolism and pharmacokinetics of naloxone. Adv Biochem Psychopharmacol. 1973;8:525\u2013535.","journal-title":"Adv Biochem Psychopharmacol"},{"key":"57_CR46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0378-4347(00)82967-9","volume":"488","author":"H. Albeck","year":"1989","unstructured":"Albeck H, Woodfield S, Kreek MJ. Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. J Chromatogr. 1989;488:435\u2013445.","journal-title":"J Chromatogr"},{"key":"57_CR47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/BF01296704","volume":"32","author":"G. Basilisco","year":"1987","unstructured":"Basilisco G, Camboni G, Bozzani A, Paravicini M, Bianchi PA. Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Dig Dis Sci. 1987;32:829\u2013832.","journal-title":"Dig Dis Sci"},{"key":"57_CR48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1046\/j.1365-2036.2001.00970.x","volume":"15","author":"N.D. Hawkes","year":"2001","unstructured":"Hawkes ND, Richardson C, Evans BK, Rhodes J, Lewis SJ, Thomas GA. Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine. Aliment Pharmacol Ther. 2001;15:625\u2013630.","journal-title":"Aliment Pharmacol Ther"},{"key":"57_CR49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neulet.2003.12.004","volume":"361","author":"P. Holzer","year":"2004","unstructured":"Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004;361:192\u2013195.","journal-title":"Neurosci Lett"},{"key":"57_CR50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0140-6736(83)91684-7","volume":"i","author":"M.J. Kreek","year":"1983","unstructured":"Kreek MJ, Schaefer RA, Hahn EF, Fishman J. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet. 1983;i:261\u2013262.","journal-title":"Lancet"},{"key":"57_CR51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/026921639601000208","volume":"10","author":"N.P. Sykes","year":"1996","unstructured":"Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996;10:135\u2013144.","journal-title":"Palliat Med"},{"key":"57_CR52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0885-3924(01)00369-4","volume":"23","author":"M. Liu","year":"2002","unstructured":"Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48\u201353.","journal-title":"J Pain Symptom Manage"},{"key":"57_CR53","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.clinthera.2008.11.008","volume":"30","author":"K. Smith","year":"2008","unstructured":"Smith K, Hopp M, Mundin G, et al. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist\/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther. 2008;30:2051\u20132068.","journal-title":"Clin Ther"},{"key":"57_CR54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpain.2008.06.012","volume":"13","author":"W. Meissner","year":"2009","unstructured":"Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56\u201364.","journal-title":"Eur J Pain"},{"key":"57_CR55","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3111\/13696990903430481","volume":"12","author":"A.M. Rentz","year":"2009","unstructured":"Rentz AM, Yu R, M\u00fcller-Lissner SA, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12:371\u2013383.","journal-title":"J Med Econ"},{"key":"57_CR56","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1185\/03007990802584454","volume":"24","author":"K. Simpson","year":"2008","unstructured":"Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone\/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate to severe noncancer pain. Curr Med Res Opin. 2008;24:3503\u20133512.","journal-title":"Curr Med Res Opin"},{"key":"57_CR57","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1517\/14656560902796798","volume":"10","author":"O. L\u00f6wenstein","year":"2009","unstructured":"L\u00f6wenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10:531\u2013543.","journal-title":"Expert Opin Pharmacother"},{"key":"57_CR58","doi-asserted-by":"crossref","unstructured":"Ballantyne JC, Carwood C. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev. 2005;(2):CD005178.","DOI":"10.1002\/14651858.CD005178"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0057-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-010-0057-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0057-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T18:05:12Z","timestamp":1740420312000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-010-0057-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,11]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["57"],"URL":"https:\/\/doi.org\/10.1007\/s12325-010-0057-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,11]]}}}